Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionDNA-binding transcription repressor activity, RNA polymerase II-specific

POU4F1 HOXD9 FEZF2

2.15e-0432083GO:0001227
GeneOntologyMolecularFunctionDNA-binding transcription repressor activity

POU4F1 HOXD9 FEZF2

2.27e-0432683GO:0001217
GeneOntologyMolecularFunctionchromatin binding

POU4F1 ARID1B FEZF2

2.46e-0373983GO:0003682
GeneOntologyMolecularFunctionRNA polymerase II cis-regulatory region sequence-specific DNA binding

POU4F1 HOXD9 FEZF2

1.07e-02124483GO:0000978
GeneOntologyMolecularFunctioncis-regulatory region sequence-specific DNA binding

POU4F1 HOXD9 FEZF2

1.13e-02127183GO:0000987
GeneOntologyBiologicalProcessperipheral nervous system neuron development

POU4F1 HOXD9

1.58e-051682GO:0048935
GeneOntologyBiologicalProcessperipheral nervous system neuron differentiation

POU4F1 HOXD9

1.58e-051682GO:0048934
GeneOntologyBiologicalProcessneuron fate commitment

POU4F1 FEZF2

5.30e-049182GO:0048663
GeneOntologyBiologicalProcessperipheral nervous system development

POU4F1 HOXD9

6.14e-049882GO:0007422
GeneOntologyBiologicalProcessnegative regulation of DNA-templated transcription

POU4F1 HOXD9 FEZF2 ZNF503

1.18e-03139984GO:0045892
GeneOntologyBiologicalProcessnegative regulation of RNA biosynthetic process

POU4F1 HOXD9 FEZF2 ZNF503

1.23e-03141384GO:1902679
GeneOntologyBiologicalProcessneuron development

POU4F1 HOXD9 ARID1B FEZF2

1.40e-03146384GO:0048666
GeneOntologyCellularComponentnuclear protein-containing complex

POU4F1 ARID1B SRSF1

1.24e-02137783GO:0140513
GeneOntologyCellularComponentchromatin

POU4F1 HOXD9 ARID1B

1.51e-02148083GO:0000785
MousePhenoincreased thermal nociceptive threshold

ARID1B RAPGEFL1

1.61e-0310882MP:0001973
MousePhenoabnormal forebrain morphology

POU4F1 ARID1B FEZF2 ZNF503

1.87e-03107284MP:0000783
MousePhenoabnormal corpus callosum morphology

ARID1B FEZF2

2.28e-0312982MP:0000780
MousePhenoabnormal dorsal telencephalic commissure morphology

ARID1B FEZF2

2.39e-0313282MP:0008219
DomainHomeobox_CS

POU4F1 HOXD9

2.66e-0318682IPR017970
DomainHomeobox

POU4F1 HOXD9

4.16e-0323482PF00046
DomainHOMEOBOX_1

POU4F1 HOXD9

4.23e-0323682PS00027
DomainHOX

POU4F1 HOXD9

4.27e-0323782SM00389
DomainHomeobox_dom

POU4F1 HOXD9

4.34e-0323982IPR001356
DomainHOMEOBOX_2

POU4F1 HOXD9

4.34e-0323982PS50071
Domain-

POU4F1 HOXD9

6.03e-03283821.10.10.60
DomainHomeodomain-like

POU4F1 HOXD9

8.22e-0333282IPR009057
Domain-

FEZF2 ZNF503

3.19e-02679823.30.160.60
DomainZnf_C2H2/integrase_DNA-bd

FEZF2 ZNF503

3.33e-0269482IPR013087
Pubmed

Reciprocal Connections Between Cortex and Thalamus Contribute to Retinal Axon Targeting to Dorsal Lateral Geniculate Nucleus.

POU4F1 FEZF2

1.67e-0698228334242
Pubmed

Zfp503/Nlz2 Is Required for RPE Differentiation and Optic Fissure Closure.

POU4F1 ZNF503

2.54e-06118236326727
Pubmed

Satb2 is a postmitotic determinant for upper-layer neuron specification in the neocortex.

FZD8 FEZF2

4.85e-06158218255031
Pubmed

m6A regulation of cortical and retinal neurogenesis is mediated by the redundant m6A readers YTHDFs.

POU4F1 ARID1B

7.90e-06198236039295
Pubmed

Regulation of retinal progenitor expansion by Frizzled receptors: implications for microphthalmia and retinal coloboma.

POU4F1 FZD8

2.15e-05318222228100
Pubmed

LSD1 co-repressor Rcor2 orchestrates neurogenesis in the developing mouse brain.

POU4F1 FEZF2

3.60e-05408226795843
Pubmed

Transcriptional Networks Controlled by NKX2-1 in the Development of Forebrain GABAergic Neurons.

FZD8 ZNF503

3.60e-05408227657450
Pubmed

WNT signaling affects gene expression in the ventral diencephalon and pituitary gland growth.

POU4F1 FZD8

5.64e-05508218351662
Pubmed

BRCA2 mediates centrosome cohesion via an interaction with cytoplasmic dynein.

FZD8 ZNF503

7.34e-05578227433848
Pubmed

Agonist-specific Protein Interactomes of Glucocorticoid and Androgen Receptor as Revealed by Proximity Mapping.

ARID1B SRSF1

1.38e-04788228611094
GeneFamilyZinc fingers C2H2-type|ZF class homeoboxes and pseudogenes

FEZF2 ZNF503

2.90e-027187228
CoexpressionBENPORATH_EED_TARGETS

POU4F1 HOXD9 FZD8 FEZF2 ZNF503

5.39e-06105985M7617
CoexpressionBENPORATH_PRC2_TARGETS

POU4F1 HOXD9 FEZF2 ZNF503

2.42e-0565084M8448
CoexpressionZHAN_MULTIPLE_MYELOMA_MS_UP

FZD8 ZNF503

9.91e-055082M19632
CoexpressionBENPORATH_SUZ12_TARGETS

POU4F1 HOXD9 FEZF2 ZNF503

1.49e-04103584M9898
CoexpressionBENPORATH_ES_WITH_H3K27ME3

POU4F1 HOXD9 FEZF2 ZNF503

1.99e-04111584M10371
CoexpressionDESCARTES_FETAL_LUNG_LYMPHATIC_ENDOTHELIAL_CELLS

POU4F1 HOXD9

2.24e-047582M40245
CoexpressionMEISSNER_NPC_HCP_WITH_H3K27ME3

HOXD9 FEZF2

2.48e-047982M1932
CoexpressionMEISSNER_NPC_HCP_WITH_H3K27ME3

HOXD9 FEZF2

2.55e-048082MM817
CoexpressionGARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_GREY_DN

FZD8 ZNF503

2.55e-048082M8565
CoexpressionDESCARTES_FETAL_HEART_SATB2_LRRC7_POSITIVE_CELLS

FEZF2 RAPGEFL1

5.25e-0411582M40201
CoexpressionGSE23114_PERITONEAL_CAVITY_B1A_BCELL_VS_SPLEEN_BCELL_UP

FZD8 ZNF503

1.44e-0319182M8287
CoexpressionGSE21927_EL4_VS_MCA203_TUMOR_MONOCYTES_DN

SRSF1 RAPGEFL1

1.47e-0319382M7586
CoexpressionGSE8515_CTRL_VS_IL6_4H_STIM_MAC_DN

HOXD9 FZD8

1.50e-0319582M5765
CoexpressionGSE22611_NOD2_VS_MUTANT_NOD2_TRANSDUCED_HEK293T_CELL_DN

HOXD9 FEZF2

1.53e-0319782M8165
CoexpressionGSE2405_0H_VS_9H_A_PHAGOCYTOPHILUM_STIM_NEUTROPHIL_UP

POU4F1 RAPGEFL1

1.54e-0319882M6217
CoexpressionGSE20484_MCSG_VS_CXCL4_MONOCYTE_DERIVED_MACROPHAGE_UP

HOXD9 SRSF1

1.56e-0319982M7384
CoexpressionGSE12366_PLASMA_CELL_VS_MEMORY_BCELL_DN

ARID1B SRSF1

1.56e-0319982M3177
CoexpressionGSE19888_ADENOSINE_A3R_ACT_VS_TCELL_MEMBRANES_ACT_AND_A3R_INH_PRETREAT_IN_MAST_CELL_DN

ARID1B RAPGEFL1

1.56e-0319982M7319
CoexpressionGSE45365_CTRL_VS_MCMV_INFECTION_NK_CELL_UP

POU4F1 HOXD9

1.57e-0320082M10026
CoexpressionGSE23502_BM_VS_COLON_TUMOR_MYELOID_DERIVED_SUPPRESSOR_CELL_DN

ARID1B SRSF1

1.57e-0320082M8088
CoexpressionGSE43955_1H_VS_60H_ACT_CD4_TCELL_WITH_TGFB_IL6_DN

HOXD9 FZD8

1.57e-0320082M9685
CoexpressionGSE5503_MLN_DC_VS_PLN_DC_ACTIVATED_ALLOGENIC_TCELL_DN

HOXD9 RAPGEFL1

1.57e-0320082M291
CoexpressionGSE10239_NAIVE_VS_KLRG1HIGH_EFF_CD8_TCELL_DN

POU4F1 ZNF503

1.57e-0320082M3054
CoexpressionGSE7852_LN_VS_FAT_TREG_DN

HOXD9 ZNF503

1.57e-0320082M5742
CoexpressionGROSS_HYPOXIA_VIA_ELK3_UP

HOXD9 SRSF1

1.73e-0321082M1303
CoexpressionGROSS_HYPOXIA_VIA_ELK3_UP

HOXD9 SRSF1

1.78e-0321382MM1125
CoexpressionAtlasFacebaseRNAseq_e8.5_Non-Floor Plate Neural Epithelium_top-relative-expression-ranked_500

FZD8 FEZF2 SRSF1 ZNF503

1.81e-0548984Facebase_RNAseq_e8.5_Non-Floor Plate Neural Epithelium_500
CoexpressionAtlasratio_induced-Ectoderm_vs_StemCell_top-relative-expression-ranked_500_k-means-cluster#1

POU4F1 FEZF2 ZNF503

1.20e-0427983ratio_ECTO_vs_SC_500_K1
CoexpressionAtlasFacebaseRNAseq_e8.5_Non-Floor Plate Neural Epithelium_top-relative-expression-ranked_1000

FZD8 FEZF2 SRSF1 ZNF503

2.68e-0497684Facebase_RNAseq_e8.5_Non-Floor Plate Neural Epithelium_1000
CoexpressionAtlasratio_induced-Ectoderm_vs_StemCell_top-relative-expression-ranked_1000_k-means-cluster#3

POU4F1 FEZF2 ZNF503

5.59e-0447183ratio_ECTO_vs_SC_1000_K3
CoexpressionAtlasFacebaseRNAseq_e10.5_Olfactory Pit_top-relative-expression-ranked_500_k-means-cluster#4

FZD8 FEZF2

5.80e-049882Facebase_RNAseq_e10.5_Olfactory Pit_500_K4
CoexpressionAtlasFacebaseRNAseq_e8.5_Non-Floor Plate Neural Epithelium_top-relative-expression-ranked_100

FEZF2 SRSF1

5.80e-049882Facebase_RNAseq_e8.5_Non-Floor Plate Neural Epithelium_100
CoexpressionAtlasFacebaseRNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_top-relative-expression-ranked_100

FZD8 FEZF2

6.04e-0410082Facebase_RNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_100
CoexpressionAtlasratio_induced-Ectoderm_vs_StemCell_top-relative-expression-ranked_100

FEZF2 ZNF503

6.04e-0410082PCBC_ratio_ECTO_vs_SC_100
CoexpressionAtlasFacebaseRNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_top-relative-expression-ranked_500

FZD8 FEZF2 SRSF1

6.39e-0449383Facebase_RNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_500
CoexpressionAtlasFacebaseRNAseq_e8.5_Floor Plate_top-relative-expression-ranked_500

FZD8 FEZF2 ZNF503

6.46e-0449583Facebase_RNAseq_e8.5_Floor Plate_500
CoexpressionAtlasratio_induced-Ectoderm_vs_StemCell_top-relative-expression-ranked_500

POU4F1 FEZF2 ZNF503

6.46e-0449583PCBC_ratio_ECTO_vs_SC_500
CoexpressionAtlasFacebaseRNAseq_e8.5_Floor Plate_top-relative-expression-ranked_500_k-means-cluster#3

FZD8 FEZF2

8.39e-0411882Facebase_RNAseq_e8.5_Floor Plate_500_K3
CoexpressionAtlasFacebaseRNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_top-relative-expression-ranked_500_k-means-cluster#4

FZD8 SRSF1

8.82e-0412182Facebase_RNAseq_e10.5_Neural Epithelium Overlying Lateral Eminence_500_K4
CoexpressionAtlasDevelopingGonad_e12.5_ovary_emap-28876_k-means-cluster#1_top-relative-expression-ranked_1000

SRSF1 ZNF503

1.02e-0313082gudmap_developingGonad_e12.5_ovary_k1_1000
CoexpressionAtlasFacebaseRNAseq_e8.5_Non-Floor Plate Neural Epithelium_top-relative-expression-ranked_500_k-means-cluster#2

FZD8 FEZF2

1.26e-0314582Facebase_RNAseq_e8.5_Non-Floor Plate Neural Epithelium_500_K2
ToppCellkidney_cells-Hypertensive_with+without-CKD|kidney_cells / Celltypes from Cells and Nuclei per compartment and clinical group

HOXD9 ARID1B ZNF503

3.96e-061888390188b60ff893754f7938fe8edab79758827168e
ToppCellPBMC-Control-Myeloid-cDC-cDC-cDC_8|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

RAPGEFL1 ZNF503

3.09e-0415182a937e3e5a63bfeb37d2cabb3177760ec583dbf11
ToppCellPBMC-Control-Myeloid-cDC-cDC-cDC_8|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

RAPGEFL1 ZNF503

3.09e-0415182cba0939a6dd3519f6890695f5b237266ca1a7941
ToppCelldroplet-Pancreas-Endocrine-18m-Epithelial-nan|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

POU4F1 SRSF1

3.73e-041668266026988509e39e41274fa0de738383219e8ff30
ToppCellPrimary_Motor_Cortex_(M1)-Neuronal-Glutamatergic_Excit-Glut_A_(CT)-Glut_CT2_L6_FEZF2-Exc_L6_FEZF2_ETV4|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types

FEZF2 ZNF503

3.87e-0416982ccb7b2daa65cb5f4c1e7a48b3bcdf0cb8f7675c3
ToppCellPND14-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC-LEC_mature|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

HOXD9 RAPGEFL1

3.96e-0417182686f95892c3909973c66c9a27159a070a068f175
ToppCellPND14-Endothelial-Endothelial_lymphatic-Lymphatic_EC-LEC|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

HOXD9 RAPGEFL1

3.96e-0417182f7ba03e7bdb687f93782c936c7b3374cc5b3b77c
ToppCellPND14-Endothelial-Endothelial_lymphatic|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

HOXD9 RAPGEFL1

3.96e-0417182d0ac50071a3854d02113c455fcc940a6ec59bbb9
ToppCellPND14-Endothelial-Endothelial_lymphatic-Lymphatic_EC|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

HOXD9 RAPGEFL1

3.96e-0417182fbf8e9db00573adcada4b25730e191417b7c9999
ToppCelldroplet-Kidney-KIDNEY-30m-Epithelial-Epcam____podocyte-3|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FZD8 RAPGEFL1

4.10e-041748276310c0af1d7df6a4de3816838b2ac2892f68746
ToppCellkidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_2|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

HOXD9 ZNF503

4.24e-0417782c9e8149639551a4c8daa90fcb2b895fdcff2e2ba
ToppCellwk_15-18-Endothelial-Blood_vessel_endothelial-OMD+_endo|wk_15-18 / Celltypes from embryonic and fetal-stage human lung

POU4F1 FZD8

4.34e-04179828c9ed247e1c4d655b81ce2f24a9936a7cade718a
ToppCellfacs-Heart-RA-24m-Mesenchymal-valve_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

HOXD9 ZNF503

4.63e-0418582c4ef8d9f8b9769e887daac4efd9dc05738b28ae2
ToppCellfacs-Heart-RA-24m-Mesenchymal-valve_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

HOXD9 ZNF503

4.63e-041858210ddf38d908525b4258f9d2da8be4c56ebc08ff4
ToppCellNeuron-Postmitotic-Excitatory_Neuron_-Deep_Layer-27|World / Primary Cells by Cluster

FEZF2 ZNF503

4.99e-0419282cf989f26c0ebdc0cd12e1e41958f063e4fa3e468
ToppCellkidney_cells-Hypertensive_with+without-CKD-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Degenerative_Distal_Convoluted_Tubule_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

HOXD9 ZNF503

4.99e-041928246ea8f4f292db70420b378c6fa3e55e99413679c
ToppCellkidney_cells-Hypertensive_with+without-CKD-Epithelial-Collecting_tubule_epithelial_cell-kidney_connecting_tubule_epithelial_cell-Connecting_Tubule_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

HOXD9 ZNF503

5.14e-04195823f517c6fc372bdcaf45b3af373414f13cbebd4ba
ToppCellkidney_cells-Hypertensive_with+without-CKD-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

HOXD9 ZNF503

5.14e-041958260d08fb27469d1e247bc47b651d7023ba82cf92f
ToppCellBrain_organoid-organoid_Kanton_Nature-Organoid-1M|organoid_Kanton_Nature / Sample Type, Dataset, Time_group, and Cell type.

SRSF1 ZNF503

5.20e-04196821e9ccbd5be7839a74108f0cd07a6d2d736bc7f1b
ToppCellkidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

HOXD9 ZNF503

5.20e-0419682f40d10ea7714067585493fdc89744714aa427de8
ToppCellkidney_cells-Renal_AKI_(acute_kidney_injury)-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Degenerative_Distal_Convoluted_Tubule_Cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

HOXD9 ZNF503

5.20e-0419682b8350340d86e4524e9616a427e7f2e116a6fb3be
ToppCell5'-GW_trimst-1.5-LargeIntestine-Mesenchymal|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

HOXD9 ZNF503

5.25e-04197825f6fce382f273e789ffbb75b63e9b4e87519918e
ToppCell(3)_Chondrocytes-(34)_Chondro-progen|(3)_Chondrocytes / Cell class and subclass of bone marrow stroma cells in homeostatis

HOXD9 ZNF503

5.25e-0419782012c49a57f9c2a3dfa988cd3882c8c6b7ef3a5ad
ToppCell5'-GW_trimst-1.5-LargeIntestine-Mesenchymal-immature_mesenchymal_cell-Mesoderm_2_(ZEB2+)|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

HOXD9 ZNF503

5.36e-0419982a95aa72387c9558e0316898eaa9df4de8932af1b
ToppCell5'-GW_trimst-1.5-LargeIntestine-Mesenchymal-immature_mesenchymal_cell|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

HOXD9 ZNF503

5.36e-0419982bb201deb281619113edcd1de2af2d3eb21b967b8
ToppCellFetal_brain-fetalBrain_Zhong_nature-GW10|fetalBrain_Zhong_nature / Sample Type, Dataset, Time_group, and Cell type.

FZD8 FEZF2

5.36e-04199828e72efcd421639ac36ed036ee13f13de070d361f
ToppCellFetal_brain-organoid_Tanaka_cellReport-GW10|organoid_Tanaka_cellReport / Sample Type, Dataset, Time_group, and Cell type.

FZD8 FEZF2

5.41e-04200827c495030e6566b81d97b5516d1972e335ce5ed8c
ToppCellNeuronal-Excitatory-eE(FEZF2_SLC17A7)-eE_1(EFTUD1P1)---L5-6|Neuronal / cells hierarchy compared to all cells using T-Statistic

FEZF2 ZNF503

5.41e-0420082046a3a4d7e4d84ee4252a695ffd4a6aee8b77070
ToppCellNeuronal-Excitatory-eE(FEZF2_SLC17A7)-eE_1(EFTUD1P1)-|Neuronal / cells hierarchy compared to all cells using T-Statistic

FEZF2 ZNF503

5.41e-0420082893cc7f6b9794da90aa0c9d721b8647dc97201cd
ToppCellNeuronal-Excitatory-eE(FEZF2_SLC17A7)-eE_1(EFTUD1P1)|Neuronal / cells hierarchy compared to all cells using T-Statistic

FEZF2 ZNF503

5.41e-04200823d677f13e429abc805a52ec2b8f36c703f511569
ToppCellBrain_organoid-organoid_Tanaka_cellReport-10w-Neuronal-Intermediate|10w / Sample Type, Dataset, Time_group, and Cell type.

HOXD9 ZNF503

5.41e-0420082e5a8647c47a49c8c90c78d681193946de103d8ff
ToppCellNeuronal-Excitatory-eE(FEZF2_SLC17A7)-eE_1(EFTUD1P1)--|Neuronal / cells hierarchy compared to all cells using T-Statistic

FEZF2 ZNF503

5.41e-042008212518f4a8d01fc66b72878cdf0ba124b37cff3d8
DrugAC1LAPJB

FEZF2 SRSF1

7.12e-061282CID000517869
DrugNiclosamide [50-65-7]; Down 200; 12.2uM; PC3; HT_HG-U133A

FZD8 SRSF1 RAPGEFL1

3.20e-05192834018_DN
Drugdimethyl-4-toluidine

ARID1B FZD8 SRSF1

7.06e-0454783ctd:C015835
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A

FZD8 SRSF1

1.54e-03172824344_DN
DrugPuromycin dihydrochloride [58-58-2]; Down 200; 7.4uM; PC3; HT_HG-U133A

FZD8 SRSF1

1.78e-03185826711_DN
DrugICI 182,780; Down 200; 1uM; MCF7; HT_HG-U133A

SRSF1 RAPGEFL1

1.84e-03188821630_DN
DrugTrichostatin A, from Streptomyces sp.; Up 200; 0.1uM; HL60; HT_HG-U133A

POU4F1 HOXD9

1.84e-03188826143_UP
Druglomustine; Down 200; 100uM; PC3; HT_HG-U133A

FZD8 SRSF1

1.84e-03188827050_DN
DrugLY 294002; Down 200; 10uM; MCF7; HT_HG-U133A_EA

SRSF1 RAPGEFL1

1.86e-03189821065_DN
Drugwortmannin; Down 200; 1uM; MCF7; HT_HG-U133A_EA

SRSF1 RAPGEFL1

1.86e-0318982869_DN
DrugNocodazole [31430-18-9]; Down 200; 13.2uM; PC3; HT_HG-U133A

FZD8 SRSF1

1.88e-03190827145_DN
DrugAzacytidine-5 [320-67-2]; Down 200; 16.4uM; MCF7; HT_HG-U133A

SRSF1 RAPGEFL1

1.88e-03190824128_DN
DrugTrichostatin A, from Streptomyces sp.; Down 200; 0.1uM; PC3; HT_HG-U133A

FZD8 SRSF1

1.88e-03190826709_DN
DrugProstaglandin E1; Up 200; 10uM; PC3; HT_HG-U133A

FZD8 SRSF1

1.88e-03190826571_UP
DrugICI182,780; Down 200; 1uM; MCF7; HT_HG-U133A

SRSF1 RAPGEFL1

1.88e-03190825926_DN
DrugICI182,780; Down 200; 1uM; MCF7; HT_HG-U133A

SRSF1 RAPGEFL1

1.90e-03191825964_DN
DrugDiphenylpyraline hydrochloride [132-18-3]; Down 200; 12.6uM; PC3; HT_HG-U133A

FZD8 SRSF1

1.90e-03191824299_DN
DrugAcacetin [480-44-4]; Down 200; 14uM; MCF7; HT_HG-U133A

POU4F1 SRSF1

1.92e-03192826044_DN
DrugMeclofenoxate hydrochloride [3685-84-5]; Up 200; 13.6uM; PC3; HT_HG-U133A

HOXD9 RAPGEFL1

1.92e-03192824268_UP
Drugscriptaid; Down 200; 10uM; PC3; HT_HG-U133A

FZD8 SRSF1

1.92e-03192826919_DN
Drugwortmannin; Down 200; 1uM; MCF7; HT_HG-U133A_EA

SRSF1 RAPGEFL1

1.92e-0319282977_DN
Drugestradiol, USP; Up 200; 0.01uM; MCF7; HT_HG-U133A

SRSF1 RAPGEFL1

1.92e-03192825238_UP
Drugtroglitazone; Down 200; 10uM; PC3; HG-U133A

FZD8 SRSF1

1.94e-0319382431_DN
DrugSulfamethoxazole [723-46-6]; Down 200; 15.8uM; PC3; HT_HG-U133A

FZD8 SRSF1

1.94e-03193823667_DN
DrugEpitiostanol [2363-58-8]; Up 200; 13uM; MCF7; HT_HG-U133A

SRSF1 RAPGEFL1

1.94e-03193824788_UP
DrugPHA-00851261E [724719-49-7]; Down 200; 10uM; PC3; HT_HG-U133A

FZD8 SRSF1

1.94e-03193823773_DN
Drugvanadyl sulfate

HOXD9 ZNF503

1.94e-0319382ctd:C034028
DrugRaloxifene hydrochloride [82640-04-8]; Down 200; 7.8uM; MCF7; HT_HG-U133A

SRSF1 RAPGEFL1

1.94e-03193826235_DN
DrugLynestrenol [52-76-6]; Down 200; 14uM; PC3; HT_HG-U133A

SRSF1 RAPGEFL1

1.96e-03194826756_DN
DrugIdoxuridine [54-42-2]; Up 200; 11.2uM; PC3; HT_HG-U133A

POU4F1 SRSF1

1.96e-03194824200_UP
DrugChlortetracycline hydrochloride [64-72-2]; Down 200; 7.8uM; PC3; HT_HG-U133A

SRSF1 RAPGEFL1

1.96e-03194826761_DN
DrugMebeverine hydrochloride [2753-45-9]; Down 200; 8.6uM; MCF7; HT_HG-U133A

POU4F1 SRSF1

1.96e-03194823193_DN
DrugTolazoline hydrochloride [59-97-2]; Down 200; 20.4uM; PC3; HT_HG-U133A

SRSF1 RAPGEFL1

1.96e-03194824262_DN
DrugGuaifenesin [93-14-1]; Down 200; 20.2uM; MCF7; HT_HG-U133A

SRSF1 RAPGEFL1

1.96e-03194823431_DN
DrugIndomethacin [53-86-1]; Down 200; 11.2uM; PC3; HT_HG-U133A

FZD8 SRSF1

1.96e-03194825049_DN
Drugestradiol, USP; Down 200; 0.01uM; ssMCF7; HG-U133A

HOXD9 RAPGEFL1

1.98e-0319582414_DN
DrugEstradiol-17 beta [50-28-2]; Up 200; 14.6uM; PC3; HT_HG-U133A

POU4F1 RAPGEFL1

1.98e-03195826718_UP
DrugCefotiam hydrochloride; Down 200; 7.2uM; PC3; HT_HG-U133A

SRSF1 RAPGEFL1

1.98e-03195826762_DN
Drugtrifluoperazine dihydrochloride; Down 200; 10uM; MCF7; HT_HG-U133A_EA

SRSF1 RAPGEFL1

1.98e-0319582910_DN
DrugLY 294002; Down 200; 10uM; MCF7; HT_HG-U133A

SRSF1 RAPGEFL1

1.98e-03195821652_DN
Drugsodium 4-phenylbutyrate; Down 200; 1000uM; PC3; HG-U133A

FZD8 SRSF1

1.98e-0319582434_DN
DrugFlurandrenolide [1524-88-5]; Down 200; 9.2uM; PC3; HT_HG-U133A

FZD8 SRSF1

2.00e-03196823679_DN
DrugBisoprolol fumarate; Down 200; 9uM; PC3; HT_HG-U133A

SRSF1 RAPGEFL1

2.00e-03196826748_DN
DrugNizatidine [76963-41-2]; Up 200; 12uM; PC3; HT_HG-U133A

SRSF1 RAPGEFL1

2.00e-03196826305_UP
DrugGly-His-Lys acetate salt; Up 200; 1uM; PC3; HT_HG-U133A

FZD8 SRSF1

2.00e-03196826570_UP
DrugAminohippuric acid [61-78-9]; Up 200; 20.6uM; MCF7; HT_HG-U133A

HOXD9 SRSF1

2.00e-03196826453_UP
DrugMethylergometrine maleate [113-42-8]; Up 200; 8.8uM; PC3; HT_HG-U133A

HOXD9 RAPGEFL1

2.00e-03196826704_UP
DrugMesalamine [89-57-6]; Up 200; 26.2uM; PC3; HT_HG-U133A

POU4F1 HOXD9

2.00e-03196825888_UP
Drugpentamidine isethionate salt; Down 200; 100uM; MCF7; HG-U133A

HOXD9 RAPGEFL1

2.02e-0319782639_DN
DrugHexestrol [84-16-2]; Up 200; 14.8uM; MCF7; HT_HG-U133A

POU4F1 RAPGEFL1

2.02e-03197826252_UP
Drugcopper(II) sulfate pentahydrate; Up 200; 100uM; MCF7; HG-U133A

HOXD9 SRSF1

2.02e-0319782575_UP
DrugNorcyclobenzaprine [303-50-4]; Down 200; 15.4uM; PC3; HT_HG-U133A

SRSF1 RAPGEFL1

2.02e-03197824190_DN
DrugIfosfamide [3778-73-2]; Down 200; 15.4uM; PC3; HT_HG-U133A

POU4F1 SRSF1

2.02e-03197825805_DN
DrugVancomycin hydrochloride [1404-93-9]; Down 200; 2.6uM; HL60; HT_HG-U133A

POU4F1 RAPGEFL1

2.02e-03197822498_DN
DrugGuanethidine sulfate [60-02-6]; Down 200; 13.4uM; MCF7; HT_HG-U133A

SRSF1 RAPGEFL1

2.02e-03197823171_DN
DrugTelenzepine dihydrochloride [147416-96-4]; Up 200; 9uM; MCF7; HT_HG-U133A

POU4F1 SRSF1

2.02e-03197827419_UP
DrugSaquinavir mesylate [149845-06-7]; Down 200; 5.2uM; MCF7; HT_HG-U133A

SRSF1 RAPGEFL1

2.02e-03197823549_DN
DrugIsotretinoin [4759-48-2]; Down 200; 13.4uM; MCF7; HT_HG-U133A

SRSF1 RAPGEFL1

2.02e-03197826017_DN
DrugBisoprolol fumarate; Down 200; 9uM; MCF7; HT_HG-U133A

SRSF1 RAPGEFL1

2.04e-03198825348_DN
DrugPyrimethamine [58-14-0]; Up 200; 16uM; MCF7; HT_HG-U133A

POU4F1 SRSF1

2.04e-03198824779_UP
Drugthioridazine hydrochloride; Down 200; 10uM; MCF7; HT_HG-U133A

SRSF1 RAPGEFL1

2.04e-03198826989_DN
DrugPancuronium bromide [15500-66-0]; Up 200; 5.4uM; MCF7; HT_HG-U133A

FZD8 RAPGEFL1

2.04e-03198824393_UP
DrugHecogenin [467-55-0]; Up 200; 9.2uM; HL60; HT_HG-U133A

POU4F1 RAPGEFL1

2.04e-03198822716_UP
DrugHesperetin [520-33-2]; Up 200; 13.2uM; PC3; HT_HG-U133A

HOXD9 FEZF2

2.04e-03198826750_UP
DrugSulfisoxazole [127-69-5]; Down 200; 15uM; PC3; HT_HG-U133A

SRSF1 RAPGEFL1

2.04e-03198824661_DN
DrugRepaglinide [135062-02-1]; Up 200; 8.8uM; PC3; HT_HG-U133A

HOXD9 RAPGEFL1

2.04e-03198825862_UP
DrugChrysin [480-40-0]; Up 200; 15.8uM; MCF7; HT_HG-U133A

POU4F1 HOXD9

2.04e-03198826485_UP
DrugDehydrocholic acid [81-23-2]; Up 200; 9.6uM; PC3; HG-U133A

HOXD9 FZD8

2.04e-03198821940_UP
DrugPHA-00745360 [351320-33-7]; Up 200; 1uM; PC3; HT_HG-U133A

SRSF1 RAPGEFL1

2.04e-03198824562_UP
DrugHexylcaine hydrochloride [532-76-3]; Up 200; 13.4uM; HL60; HT_HG-U133A

FZD8 RAPGEFL1

2.04e-03198822708_UP
DrugLoracarbef [121961-22-6]; Down 200; 10.8uM; MCF7; HT_HG-U133A

SRSF1 RAPGEFL1

2.04e-03198825492_DN
DrugN6-methyladenosine [1867-73-8]; Down 200; 14.2uM; MCF7; HT_HG-U133A

SRSF1 RAPGEFL1

2.04e-03198822626_DN
DrugCondelphine [7633-69-4]; Up 200; 8.8uM; PC3; HT_HG-U133A

HOXD9 SRSF1

2.06e-03199826357_UP
DrugFlutamide [13311-84-7]; Up 200; 14.4uM; PC3; HT_HG-U133A

SRSF1 RAPGEFL1

2.06e-03199824539_UP
Drug(+,-)-Octopamine hydrochloride [770-05-8]; Up 200; 21uM; MCF7; HT_HG-U133A

HOXD9 SRSF1

2.06e-03199826491_UP
DrugCloxacillin sodium salt [642-78-4]; Up 200; 8.8uM; MCF7; HT_HG-U133A

POU4F1 HOXD9

2.06e-03199822289_UP
DrugConessine [546-06-5]; Up 200; 11.2uM; MCF7; HT_HG-U133A

POU4F1 SRSF1

2.06e-03199824777_UP
Drugnovobiocin sodium, USP; Up 200; 100uM; ssMCF7; HG-U133A

HOXD9 SRSF1

2.06e-0319982499_UP
DrugEquilin [474-86-2]; Up 200; 15uM; PC3; HT_HG-U133A

POU4F1 RAPGEFL1

2.06e-03199824659_UP
DrugPropranolol hydrochloride [318-98-9]; Down 200; 13.6uM; PC3; HT_HG-U133A

SRSF1 RAPGEFL1

2.06e-03199826759_DN
DrugDiethylcarbamazine citrate [1642-54-2]; Up 200; 10.2uM; PC3; HT_HG-U133A

POU4F1 HOXD9

2.06e-03199825066_UP
DrugFlucytosine [2022-85-7]; Up 200; 31uM; PC3; HT_HG-U133A

HOXD9 RAPGEFL1

2.06e-03199826690_UP
DrugL(-)-vesamicol hydrochloride [112709-59-8]; Up 200; 13.6uM; HL60; HT_HG-U133A

FZD8 RAPGEFL1

2.06e-03199823118_UP
Drugestradiol, USP; Up 200; 0.01uM; ssMCF7; HG-U133A

HOXD9 RAPGEFL1

2.06e-0319982373_UP
Drugtamoxifen citrate; Up 200; 1uM; ssMCF7; HG-U133A

HOXD9 RAPGEFL1

2.08e-0320082375_UP
DiseaseLiver carcinoma

HOXD9 ARID1B

7.70e-0350782C2239176

Protein segments in the cluster

PeptideGeneStartEntry
RPGAGGGGGGGGGGG

ARID1B

386

Q8NFD5
GPGGGGGPGGGGGPG

POU4F1

146

Q01851
GGPGGGGGPGGGPGG

POU4F1

151

Q01851
GGGPGGGPGGGGGGG

POU4F1

156

Q01851
GGPGGGGGGGPGGGG

POU4F1

161

Q01851
GGGGGPGGGGGGPGG

POU4F1

166

Q01851
GGGGGGGGGGPGRGP

HOXD9

131

P28356
GGGPGGGGGGGPGGG

FZD8

641

Q9H461
GGGGGGPGGGGGPGG

FZD8

646

Q9H461
GGGGGGGGGGGGAPV

FEZF2

106

Q8TBJ5
KEPGGGGGGGGGGGG

ZNF503

186

Q96F45
GRGGGGGGGGGAPRG

SRSF1

96

Q07955
CGGPGGGGGPGGGGG

RAPGEFL1

31

Q9UHV5
GGGGPGGGGGPAGGQ

RAPGEFL1

36

Q9UHV5